What are the recommended treatment steps and dosing for eczema based on severity?

Eczema Treatment Steps with Doses

Start with intensive emollient therapy (1500g/month minimum) combined with medium-to-high potency topical corticosteroids once daily for 1-4 weeks to gain control, then transition to proactive maintenance therapy with twice-weekly application to prevent flares.

Step 1: Initial Clearance Phase (1-4 weeks)

Emollients - Foundation of All Treatment

• Dose: Minimum 1500g (or mL) per month for children 1
• Apply liberally and frequently throughout the day
• Use before applying topical corticosteroids
• Continue indefinitely as baseline therapy

Topical Corticosteroids (TCS) - Primary Anti-inflammatory

Potency selection by age and location:

• Adults and adolescents: High-potency (Class I-III US, Class III-IV Europe) once daily 2
• Children: Medium-potency preferred; reserve highest potencies for adolescents 2
• Sensitive areas (face, genitals, intertriginous): Lower potency or calcineurin inhibitors

Application frequency: Once daily is equally effective as twice daily for potent TCS 3. This is critical - more frequent application does not improve outcomes but increases cost and side effect risk.

Duration: 1-4 weeks for initial control 2

Alternative Topical Anti-inflammatories

• Tacrolimus ointment (0.03% children, 0.1% adults): For face, eyelids, and long-term use
• Pimecrolimus cream (1%): Similar indications to tacrolimus
• Delgocitinib ointment: Newer topical JAK inhibitor option 4
• Difamilast ointment: PDE4 inhibitor alternative 4

Step 2: Maintenance/Proactive Therapy

After achieving control, transition to weekend (proactive) therapy:

• Medium-potency TCS or tacrolimus: Apply 2-3 times weekly to previously affected areas, even when skin appears normal 2
• Evidence: Reduces flare risk from 58% to 25% (RR 0.43) 3
• Duration: Continue for 16-20 weeks or longer 3
• Continue daily emollients

Step 3: Systemic Therapy - When Topicals Fail

Indications for systemic therapy 2, 5:

• Failure of intensive topical therapy after appropriate trial
• Disease significantly impacting quality of life
• Topical regimen too complex to be feasible

First-Line Systemic Options

Dupilumab (FDA-approved biologic):

• Adult dose: 600mg loading, then 300mg subcutaneous weekly 2
• Efficacy: 42% reduction in severity scores 2
• Monitoring: None required 2
• Side effects: Injection site reactions, conjunctivitis

Cyclosporine (most rapid-acting):

• Dose: 2.5-5 mg/kg/day (adults and pediatrics) 2
• Efficacy: 73% reduction in severity 2
• Monitoring: CBC, CMP, magnesium, uric acid, lipids, blood pressure 2
• Side effects: Renal insufficiency, hypertension

Second-Line Systemic Options

JAK Inhibitors 4, 6:

• Baricitinib, upadacitinib, abrocitinib
• Oral administration, rapid onset
• Require monitoring for infections, thrombosis

Methotrexate:

• Adult dose: 7.5-25mg weekly 2
• Pediatric dose: 0.2-0.7 mg/kg weekly 2
• Monitoring: CBC, CMP, hepatotoxicity surveillance

Azathioprine:

• Adult dose: 1-3 mg/kg/day 2
• Pediatric dose: 1-4 mg/kg/day 2
• Monitoring: CBC, CMP, thiopurine methyltransferase before starting 2
• Efficacy: 26-39% reduction 2

Other biologics 4, 6:

• Tralokinumab: IL-13 inhibitor
• Nemolizumab: IL-31 receptor antagonist (anti-pruritic)
• Lebrikizumab: IL-13 inhibitor

Step 4: Adjunctive Therapies

Phototherapy

• UVB 311nm or UVA1 preferred 7
• For moderate-to-severe disease unresponsive to topicals
• Requires specialized equipment and multiple visits

Infection Management

Critical: Treat bacterial or viral infections before escalating therapy 2

• Most patients colonized with Staphylococcus aureus
• Consider dilute bleach baths for recurrent infections 5

Critical Pitfalls to Avoid

1. Underdosing emollients: Most children receive far less than the 1500g/month needed 1. Prescribe adequate quantities.

2. Steroid phobia: Once-daily potent TCS for 1-4 weeks has minimal risk. In trials, only 1% developed skin thinning, mostly with very potent formulations 3. The risk of undertreating exceeds the risk of appropriate TCS use.

3. Premature systemic therapy: Must document failure of intensive topical therapy first, ideally in a supervised setting if adherence is uncertain 2

4. Twice-daily TCS application: No additional benefit over once daily for potent steroids 3. Save money and reduce exposure.

5. Reactive-only treatment: Proactive maintenance therapy is superior to treating only when flares occur 3

6. Ignoring feasibility: Complex topical regimens that patients cannot realistically follow justify moving to systemic therapy 2